GLP-1s and the kidneys: what FLOW showed, and the dehydration risk
Reviewed 17 sourcesPublished by PepVault
Ozempic is approved to slow kidney disease after the FLOW trial, yet every GLP-1 label warns of kidney injury from dehydration. Both sides, label by label.

- Last reviewed
- Sources
- 17
- Questions
- 8
- Compounds
- 2
The short answer
GLP-1s cut both ways for the kidneys. In the FLOW trial, semaglutide 1 mg cut major kidney events, counted with heart deaths, by 24% in people with type 2 diabetes and kidney disease, and Ozempic is FDA-approved for that use. But Ozempic, Wegovy, Mounjaro and Zepbound all warn of sudden kidney injury, mostly after vomiting or diarrhoea dried someone out. Drinking enough is the labels' protection.
- FLOW: 18.7% on semaglutide 1 mg against 23.2% on placebo had a major kidney event or heart death over a median 3.4 years; Ozempic gained the kidney indication on January 28, 2025.
- In SELECT, people with obesity and heart disease but no diabetes had fewer kidney events on semaglutide 2.4 mg (1.8% against 2.2%).
- Tirzepatide has no kidney outcome trial yet; in the SURPASS-CVOT heart trial, kidney events came 23% less often than on dulaglutide (6.0% against 7.6%).
- Kidney injury was uncommon in the weight trials (Zepbound 0.5% against 0.2%); the labels tie most reported cases to dehydration from vomiting or diarrhoea, and Wegovy's says it came more often during dose steps.
Evidence: One finished phase 3 kidney outcome trial (FLOW, semaglutide 1 mg in type 2 diabetes with kidney disease) behind an FDA indication; prespecified kidney analyses of SELECT and a 24-week trial for semaglutide without diabetes; exploratory analyses of two diabetes trials (SURPASS-CVOT, SURPASS-4) and a review for tirzepatide, with no kidney outcome trial yet; the kidney-injury warning rests on postmarketing reports and low trial rates.

Are GLP-1s good or bad for your kidneys?
Over years, the evidence points to good. Semaglutide is the only GLP-1 with a finished trial built to count kidney outcomes, and it slowed kidney disease6. Over days, the risk is fluid loss. A GLP-1 (pepvault.app/glossary/glp-1; a drug that copies the gut hormone that slows the stomach and quiets appetite) can cause nausea, vomiting and diarrhoea, and a body that loses more water than it takes in sends less blood through the kidneys. Every label covered here carries the same warning for that reason1234.
Two kidney tests run through this page. eGFR (estimated glomerular filtration rate) is worked out from a blood test and says how much blood the kidneys filter each minute; under 15 counts as kidney failure6. UACR (urine albumin-to-creatinine ratio) measures albumin, a protein that leaks into the urine when the kidney's filters are damaged.

What did the FLOW trial find?
FLOW enrolled 3,533 adults with type 2 diabetes and chronic kidney disease, with an eGFR of 25 to 75 and albumin in the urine, nearly all already on a standard kidney-protecting blood pressure drug1. Half took semaglutide 1 mg a week, half a placebo (pepvault.app/glossary/placebo; a dummy shot)6. The trial was stopped early on the advice given at a planned interim check, after a median of 3.4 years6.
| Outcome in FLOW | Semaglutide 1 mg (1,767) | Placebo (1,766) | Hazard ratio |
|---|---|---|---|
| Main composite: kidney failure, eGFR halved, or death from kidney or heart causes | 18.7% | 23.2% | 0.76 |
| eGFR fell by half or more, and stayed there | 9.3% | 12.1% | 0.73 |
| eGFR under 15 (the kidney failure range) | 5.2% | 6.2% | 0.80 |
| Started dialysis or had a transplant | 4.9% | 5.7% | 0.84 |
| Heart-related death | 7.0% | 9.6% | 0.71 |
| Death from any cause | 12.8% | 15.8% | 0.80 |
Rows from the Ozempic label's Table 101. A hazard ratio of 0.76 means the event came 24% less often over time. The kidney failure and dialysis rows, taken alone, had confidence intervals that crossed 1; the kidney-only composite was lower on semaglutide (hazard ratio 0.79)16.
The slower decline is the part a person feels over years: eGFR fell 1.16 points a year less on semaglutide6. Serious adverse events were fewer on the drug, 49.6% against 53.8%6, and the label lists no new serious reaction from the trial1. One open question: among the 550 people already taking an SGLT2 inhibitor, the other main kidney drug class, the benefit did not show (41 against 38 events), and the authors, who call the kidney results consistent in both groups, note the subgroup was too small to detect a smaller benefit7.
On January 28, 2025 the FDA approved Ozempic to reduce the risk of sustained eGFR decline, end-stage kidney disease and heart-related death in adults with type 2 diabetes and chronic kidney disease5. For that use the label sets the lasting dose at 1 mg a week, reached after at least four weeks on 0.5 mg1. The FLOW study page (pepvault.app/research/semaglutide-flow-2024) has the full design.
Does semaglutide protect the kidneys without diabetes?
The trials point that way, though no label claims it yet. SELECT (pepvault.app/research/semaglutide-select-2024) gave semaglutide 2.4 mg, the Wegovy dose, to 17,604 adults with overweight or obesity and heart disease but no diabetes. A combined kidney outcome, which counted new heavy albumin leaks as well as kidney failure and halved eGFR, came in 1.8% on the drug against 2.2% on placebo (hazard ratio 0.78), and at week 104 eGFR sat 0.75 points higher on the drug, 2.19 points in people who started below 608.
In the smaller SMART trial, 101 adults with kidney disease, a BMI of 27 or more and no diabetes saw albumin in the urine fall 52.1% against placebo after 24 weeks of semaglutide 2.4 mg10. A 2026 analysis that pooled FLOW, SELECT and the oral-semaglutide trial SOUL, 30,787 people in all, found 16% fewer of the same combined kidney and heart-death outcome FLOW used (hazard ratio 0.84)9. FLOW and the pooled analysis were funded by Novo Nordisk, which makes semaglutide69.
What is known for tirzepatide (Mounjaro and Zepbound)?
Less, and nothing on the label yet. No trial has yet had kidney failure or dialysis as its main result for tirzepatide, and neither label carries a kidney use34. The largest signal is SURPASS-CVOT, a double-blind heart trial in 13,165 people with type 2 diabetes and heart disease: over a median 4 years, a combined kidney outcome came 23% less often on tirzepatide than on dulaglutide (Trulicity), 6.0% against 7.6% (hazard ratio 0.77), mostly through fewer new heavy albumin leaks17. An earlier look back at SURPASS-4, an open-label trial in 2,002 people, most with normal kidney function, found eGFR falling 1.4 points a year on tirzepatide against 3.6 on insulin glargine12. Both are exploratory analyses of trials built for other questions, so they suggest rather than prove.
A 2026 review of ten tirzepatide trials found albumin lowered against insulin, no clear effect on eGFR, and called for trials built around kidney outcomes13. Lilly's TREASURE-CKD, a phase 2 trial in 134 people with overweight or obesity and kidney disease whose main measure is fat inside the kidney's hollow centre (renal sinus fat) on MRI, finished in July 2026; no results were posted on ClinicalTrials.gov as of November 202614.
Can a GLP-1 cause kidney damage?
Yes, through dehydration, and the labels say so in nearly the same words. Ozempic's reads: "There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide. The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea"1. Acute kidney injury means the kidneys' filtering drops over hours or days. In the trials it was uncommon:
| Label | Kidney use on the label | Kidney injury in its trials | Dose change for kidney disease |
|---|---|---|---|
| Ozempic (semaglutide) | Yes: type 2 diabetes with kidney disease | No trial rate given; postmarketing reports | None recommended |
| Wegovy (semaglutide) | No | 0.4 against 0.2 cases per 100 patient-years (7 against 4 people), weight trials | None listed; drug levels unchanged at eGFR 30 to 89 |
| Mounjaro (tirzepatide) | No | No trial rate given; postmarketing reports | None recommended |
| Zepbound (tirzepatide) | No | 0.5% against 0.2%, SURMOUNT-1 and -2, up to 72 weeks | None recommended |
From each label's warnings (section 5), adverse reactions (6.1 and 6.2), kidney impairment (8.6) and pharmacokinetics (12.3)1234. Rates from different trials are not a head-to-head comparison. Each brand page has the rest of its label: Ozempic (pepvault.app/drugs/ozempic), Wegovy (pepvault.app/drugs/wegovy), Mounjaro (pepvault.app/drugs/mounjaro) and Zepbound (pepvault.app/drugs/zepbound).
Wegovy's label adds who is most exposed: kidney side effects were more common in people who already had reduced kidney function, and occurred more often during dose titration2. Kidney disease does not change the dose on the Ozempic, Mounjaro or Zepbound labels, because drug levels stay the same down to kidney failure134; what changes is the watching. Whether a GLP-1 fits a person with kidney disease, and which, is the prescriber's decision, often with a kidney specialist.
When is the dehydration risk highest, and what helps?
In the first weeks and after each dose step. All four labels tell prescribers to check kidney function in people with stomach side effects that could dry them out, "especially during dosage initiation and escalation"1234, and the Ozempic label notes that most nausea, vomiting and diarrhoea came during dose escalation1 (the full list: pepvault.app/peptides/semaglutide/side-effects). The patient guides give the plan in plain words: "It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away"1234. On a bad stomach day that looks like this:
- Keep fluids going in small sips through the day, since a full glass on a queasy stomach often comes back up.
- Notice how much you are passing: much less urine than usual is one of the signs of kidney trouble15.
- Write down what happened and when, so the pattern is clear if it lasts.
- Call your prescriber right away if the vomiting or diarrhoea does not go away1234.
PepVault's side-effect log records each symptom with its date, a severity from 1 to 5 and a note, beside the compound it belongs to, so you can show your prescriber which weeks brought it on. Log it in PepVault
Commonly reported: people on a GLP-1 often say they drink less without noticing, because they eat less and the drinks that came with meals go too; many find a bottle kept in sight easier than remembering to drink.
What does kidney pain on a GLP-1 mean?
None of the four labels lists kidney pain as a side effect1234. Pain in the side or back between the ribs and hip, called flank pain, has two kidney causes worth knowing. One is a kidney stone, which brings sharp pain in the back, side, lower belly or groin, sometimes with blood in the urine16; in SELECT, stones were reported in 1.2% on Wegovy against 0.8% on placebo2. The other is acute kidney injury itself, where flank pain can come with little or no urine and swelling in the legs or ankles15. Ordinary back pain from muscles is far more common than either.
When to get help Sharp side or back pain, blood in the urine, very little urine, or vomiting and diarrhoea you cannot keep up with are reasons to contact your prescriber the same day11516.
Will losing weight change your eGFR result?
Probably not much. eGFR is usually worked out from creatinine, a waste product of muscle, so doctors have asked whether losing muscle on a GLP-1 makes the kidneys look better than they are. In SMART, people lost 9.1 kg against placebo, and the changes in weight, lean mass and fat mass did not track the changes in eGFR, whether estimated from creatinine, from cystatin C (a second marker not made by muscle) or measured directly11. The authors concluded that a 10% weight loss on semaglutide does not distort the estimate11.
PepVault's Bloodwork page keeps creatinine and eGFR by date, and your weigh-ins sit on their own chart, so each result your prescriber orders lines up with the months of treatment it came from. Track your weight in PepVault
Sources
- Ozempic (semaglutide) injection, prescribing information and Medication Guide (§1, §2.2, §5.6, §6.1, §8.6, §14.3 and Table 10). Novo Nordisk. DailyMed, SPL version 20, effective June 2026. dailymed.nlm.nih.gov
- Wegovy (semaglutide) injection and tablets, prescribing information and Medication Guide (§5.5, §6.1, §12.3). Novo Nordisk. DailyMed, SPL version 19, June 2026. dailymed.nlm.nih.gov
- Mounjaro (tirzepatide) injection, prescribing information and Medication Guide (§1, §5.5, §6.2, §8.6). Eli Lilly and Company. DailyMed, SPL version 40, August 2026. dailymed.nlm.nih.gov
- Zepbound (tirzepatide) injection, prescribing information and Medication Guide (§1, §5.3, §6.1, §8.6). Eli Lilly and Company. DailyMed, SPL version 40, revised August 2026. dailymed.nlm.nih.gov
- US FDA. Supplement approval letter, NDA 209637/S-025 (Ozempic): new indication to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. January 28, 2025. accessdata.fda.gov
- Perkovic V et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391(2):109-121. PubMed 38785209
- Mann JFE et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med. 2024;30(10):2849-2856. PubMed 38914124
- Colhoun HM et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30(7):2058-2066. PubMed 38796653
- Mann JFE et al. Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis. Lancet Diabetes Endocrinol. 2026;14(10):818-830. PubMed 42567173
- Apperloo EM et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial (SMART). Nat Med. 2025;31(1):278-285. PubMed 39455729
- Heerspink HJL et al. Effects of semaglutide on body composition and GFR: a prespecified analysis of the SMART trial. Clin J Am Soc Nephrol. 2026;21(7):1149-1158. PubMed 42308057
- Heerspink HJL et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(11):774-785. PubMed 36152639
- Li S et al. Kidney effects of tirzepatide across albuminuria, filtration markers, and clinical outcomes: a parent-trial-level systematic review and meta-analysis. Diabetes Res Clin Pract. 2026 (online November 13). PubMed 43025465
- ClinicalTrials.gov. TREASURE-CKD: tirzepatide in overweight or obesity and chronic kidney disease with or without type 2 diabetes (NCT05536804). Eli Lilly and Company. Record updated September 2026. clinicaltrials.gov
- MedlinePlus (US National Library of Medicine). Acute kidney failure. Reviewed April 30, 2026. medlineplus.gov
- National Institute of Diabetes and Digestive and Kidney Diseases (NIH). Symptoms and causes of kidney stones. niddk.nih.gov
- Zoungas S et al. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. Lancet Diabetes Endocrinol. 2026;14(7):544-557. PubMed 42114520
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.